ISRIB (Integrated Stress Response Inhibitor) is a small molecule compound that enhances [eIF2B](/proteins/eif2b1-protein) activity by stabilizing the eIF2B decamer, counteracting the effects of [eIF2α](/proteins/eif2s1-protein) phosphorylation. Unlike traditional approaches that aim to block the entire Integrated Stress Response (ISR), ISRIB works downstream to restore [protein synthesis](/mechanisms/protein-synthesis-neurodegeneration) while preserving the adaptive stress response[@grosely2022][@costamattioli2023].
ISRIB represents a paradigm shift in ISR modulation: rather than inhibiting the stress-sensing kinases (PERK, GCN2, PKR, HRI), it directly targets the translation machinery to restore productive protein synthesis. This approach has shown promise in preclinical models of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and [frontotemporal dementia](/diseases/frontotemporal-dementia)[@wang2023].
Mechanism of Action
ISR Biology and Pathophysiology
The [Integrated Stress Response](/mechanisms/integrated-stress-response) is a fundamental cellular protective mechanism activated by various stressors:
Stress Sensing: Four PERK-like kinases sense different cellular stresses
Restores synaptic protein synthesis without blocking adaptive stress response
Enhances cognitive function in models of memory impairment
Promotes neuronal survival under proteostatic stress["@harding2021"][@scheper2022]
Key Molecular Targets
Preclinical Evidence
Alzheimer's Disease Models
5xFAD mice: ISRIB treatment improved memory performance in Morris water maze, reduced amyloid-beta plaque burden, and restored synaptic marker expression (PSD95, synaptophysin)[@xfad2023]
APP/PS1 mice: Improved cognitive function and reduced tau phosphorylation via restored protein synthesis capacity[@appps2023]
In vitro neuronal cultures: Protected against amyloid-beta oligomer-induced synaptic dysfunction
Parkinson's Disease Models
α-synuclein transgenic mice: ISRIB reduced dopaminergic neuron loss and improved motor function through improved protein folding capacity[@synuclein2023]
MPTP parkinsonian models: Protected against mitochondrial toxin-induced neurotoxicity
LRRK2 G2019S models: Restored translational capacity impaired by mutant LRRK2
ALS/FTD Models
TDP-43 models: ISRIB counteracted TDP-43-induced ISR dysregulation and improved motor neuron survival[@tdp2023]
C9orf72 models: Reduced pro-apoptotic signaling from dipeptide repeat proteins
SOD1 models: Delayed disease onset and extended survival
CBS/PSP Models
4R-tau models: ISRIB addressed protein stress common to tauopathies
Evidence gap: Direct ISRIB testing in CBS/PSP models is limited, but biological plausibility is strong based on shared proteostasis mechanisms
Cross-Disease Rationale
Common ISR Dysregulation Across Neurodegeneration
The ISR is a convergent mechanism across neurodegenerative diseases, making ISRIB a potentially broad-spectrum neuroprotective therapy[@convergent2023].
Drug Candidates
ISRIB (Integrated Stress Response Inhibitor)
Original developer: UCSF (Peter Walter lab)
Mechanism: eIF2B activator/stabilizer
Status: Preclinical/early clinical
Challenge: Brain penetration (being addressed with analogs)
ISRIB Analogs in Development
Related Compounds
CGS-21680 (A2A receptor agonist): Shown to enhance eIF2B activity in some studies
Metformin: Indirectly modulates ISR via AMPK
Rapamycin: mTOR inhibition → indirect ISR effects
Clinical Trial Status
Current Trials
As of 2026, ISRIB and analogs are in preclinical/early clinical development. No large-scale Phase 2/3 trials have completed for neurodegenerative indications.
Development Challenges
Brain penetration: Original ISRIB has limited CNS exposure
Dosing strategy: Chronic vs. intermittent dosing unclear
Biomarker development: Need patient stratification biomarkers
Therapeutic Considerations
Combination Therapy Potential
ISRIB is well-suited for combination approaches:
With autophagy inducers ([rapamycin](/therapeutics/mtor-inhibitor-therapy), [trehalose](/therapeutics/autophagy-enhancers)): Synergistic proteostasis restoration
With chaperone inducers: Enhanced protein folding capacity
With antioxidants: Address oxidative stress upstream
With anti-inflammatory agents: Reduce neuroinflammation-driven ISR[@isrib2024]
Patient Selection
Potential biomarkers for patient stratification:
eIF2α phosphorylation in CSF or blood
ATF4 target gene expression in peripheral mononuclear cells
Stress granule formation in neurons (imaging)
NfL levels: Neurofilament light chain as disease progression marker
Safety Profile
Preclinical Safety Observations
Well-tolerated in mouse and rat models at effective doses
No significant toxicity in chronic dosing studies (up to 6 months in rodents)